12 Furazadrol ([1',2']isoxazolo[4',5':2,3]-5α-androstan-17β-ol) is a designer anabolic androgenic steroid that is 13 readily available via the internet. It contains an isoxazole fused to the steroid A-ring which offers metabolic 14 stability and noteworthy anabolic activity raising concerns over the potential for abuse of this compound in 15 equine sports. The metabolism of furazadrol was studied by in vivo and in vitro methods for the first time. 16
Over past decades numerous instances of the use of androgenic anabolic steroids (AAS) as performance 32 enhancing drugs have been documented resulting in prohibition by the majority of sporting governing 33 bodies [1] . In order to enforce these bans, analytical methods which primarily utilise gas or liquid 34 chromatography coupled to detection by mass spectrometry (GC-MS or LC-MS) have been 35
developed [2] 
Instruments

88
Melting points were determined using a SRS (Sunnyvale CA, USA) Optimelt MPA 100 melting point 89 apparatus and are uncorrected. high-resolution mass spectrometry (HRMS) were performed using positive electron ionisation (+EI) on a 97
Micromass VG Autospec mass spectrometer or negative electrospray ionization (-ESI) 
Analytical Methods
103
Positive mode liquid chromatography-high resolution accurate mass (LC-HRAM) spectrometry analysis was 104 undertaken using a Thermo Fisher Scientific (Bremen, Germany) Ultimate 3000 HPLC coupled to an Q 105 Exactive Hybrid Quadrupole Orbitrap or an Exactive Plus Orbitrap mass spectrometer equipped with a 106 Waters SunFire C18 column (100 x 2.1 mm, 3.5 um) eluting with a gradient consisting of the following 107 127 An aliquot of urine (2 mL) was fortified with d3-testosterone 17-sulfate (100 ng mL -1 ) internal standard and 128 treated with sodium phosphate buffer (100 mM, pH 7.4, 1 mL) and centrifuged (2000 rpm, 5 min) to pelletsolids. The supernatant was then loaded onto an Oasis WAX SPE cartridge (3 cc) that was pre-conditioned 130 with methanol (1 mL) and water (2 mL), and then washed with aqueous sodium hydroxide solution (0.1 M, 131 2 mL), sodium phosphate buffer (0.1 M, pH 7.4, 2 mL) and water (2 mL The sulfate fraction from section 2.5.3 above was reconstituted in tris(hydroxymethyl)amino-methane 147 buffer (0.1 M, pH 9.0, 2 mL) and a solution of P. aeruginosa arylsulfatase (70 mg/mL, 50 µL) was added [24] . 148
Sample Preparation without fractionation
The solution was incubated at 37 o C for 18 h before being subjected to purification by SPE without 149 fractionation as per 2.5. 161 Duplicate aliquots of blank equine urine (2 mL) were fortified with d3-testosterone 17-sulfate (100 ng mL 183 An aliquot of urine (3 mL) was adjusted to pH 5.0-5.5 using aqueous hydrochloric acid solution (3 M) and a 184 solution of internal standard containing d4-hydrocortisone (1.5 μg mL The LOD was estimated as described in section 2. In addition, a number of predicted phase I metabolites of F were selected based on the equine metabolism 202 of structurally similar steroidal agents, and these were synthesised in an effort to unambiguously identify 203 the metabolites derived from in vivo and in vitro metabolism studies [27] . Negative mode analysis showed that furazadrol was primarily excreted without phase I transformation as 235 the sulfate conjugate ( Table 1) . Metabolites corresponding to FS (Figure 1 ) and IFS were identified and 236 matched against synthetic reference materials. As the administered drug was a 10:1 mixture of F and IF, 237 metabolites derived from both isomers were observed in the in vivo samples, with IF giving rise to a 238 number of minor metabolites. Since there appeared to be little discernible difference in the metabolism of 239 each isomer in the mixture, metabolism is described for the major isomer only. Hydroxylated furazadrol 240 sulfate (S1), and two oxidised and hydroxylated furazadrol sulfate metabolites (S2, S3) were also observed 241 as minor metabolites. No EFS was detected by comparison with the synthetically-derived reference 242 material. Although glucuronide metabolites were detected by negative mode analysis, the sensitivity was 243 significantly lower than that observed under positive mode analysis [28] . 244 Figure 1 .
Quantification of furazadrol 17-sulfate (FS) in equine urine
Translation to routine screening
245
Positive mode analysis showed that furazadrol was also primarily excreted without phase I transformation 246 as the glucuronide conjugate ( Table 1) . Metabolites corresponding to FG (Figure 2 ) and IFG were identified 247 and matched against reference materials. Minor EFG was also observed and matched against the reference 248 material. Epimerisation of the C17 alcohol, through a two-step oxidation and reduction sequence is 249 typically observed as a significant pathway for a range of steroids including boldenone [27] [29]. 250
Additionally, a minor oxidised and hydroxylated furazadrol glucuronide metabolite (G1) was also detected. arylsulfatase, a purified enzyme with steroid sulfate hydrolysis activity comparable to commercially 275 available crude enzyme preparations but without glucuronidase, oxidase or reductase activity [24] . 276
Treatment of the sulfate extract at 37 °C overnight (section 2.5.5) followed by SPE without fractionation 277 afforded the sulfatase hydrolysed extract. Hydrolysis of FS (major) and IFS in the urine gave rise to F (major) 278
and IF respectively and these were matched against reference materials by positive mode LC-MS analysis 279 (section 2.4). Additionally, hydrolysis of the minor hydroxylated (S1), and oxidised and hydroxylated 280 furazadrol sulfate metabolites (S2, S3) gave rise to peaks corresponding to one hydroxylated furazadrol 281 (M3, see section 3.5), and one oxidised and hydroxylated furazadrol metabolite respectively. A second 282 oxidised and hydroxylated furazadrol metabolite was not observed. Residual sulfate metabolites were not 283 observed by negative mode LC-MS analysis of the enzyme hydrolysed extract (section 2.4). 284 285 Having identified FG and FS as the major equine metabolites following oral administration attention turned 286 to establishing the quantification of these metabolites. Although the detection of exogenous steroids or 287 their metabolites is sufficient grounds for prosecution in the racing industry, the investigation of excretion 288 profiles provides information relevant to the development of screening strategies for illicit substances. 289
Quantification of in vivo equine metabolites in equine urine
Calibrators were generated from separately spiking blank urine with FG and FS reference materials which 290 were subjected to sample preparation (section 2.5.2) and LC-MS analysis (section 2.4) to generate a 291 calibration plot. The plots were linear over the range 1-1500 ng mL ) for this analyte. No metabolites were detected beyond the 24 h sample. The excretion profile for the 297 major urinary metabolites is presented below (Figure 3) . 298 hepatocytes, microsomes or S9 fraction offer convenient systems to study the in vitro metabolism of 304 steroid compounds. A key question associated with the use of in vitro metabolic platforms is how closely 305 such systems replicate the metabolism observed in vivo. To address this question a brief phase I in vitro 306 metabolism study of furazadrol was conducted using equine liver S9 fraction to compare the metabolic 307 profile generated. 308
The in vitro metabolism of furazadrol using equine liver S9 fraction afforded a range of metabolites (Table  309 2). These included EF, EIF, OF and OIF that were matched to reference materials. The study also gave rise to 310 a number of additional unidentified metabolites including eight hydroxylated furazadrol isomers (M1-M8), 311 one oxidised and hydroxylated furazadrol isomer (M9) and two dihydroxylated furazadrol isomers (M10, 312 M11). 313 showed that a number of the metabolites were common. These included EF, and one unidentified oxidised 321 and hydroxylated furazadrol (G1  M9) observed following hydrolysis of the glucuronide fraction, and one 322 unidentified hydroxylated furazadrol (S1  M3) following hydrolysis of the sulfate fraction. However, a 323 second oxidised and hydroxylated furazadrol metabolite observed following hydrolysis of the sulfate 324 fraction (S2 or S3) was not detected in vitro. Despite this reasonable comparison, it was not possible to 325 distinguish based on relative abundance or other criteria which of the many in vitro metabolites formed 326 would likely arise in vivo. Thus the ability of this phase I in vitro study to identify key in vivo metabolites 327 appears to be limited and highlights a major challenge in using in vitro methods for metabolic profiling. 328
These differences in metabolic profile could arise from a range of factors including different enzyme 329 activities or cofactor regeneration rates within the two systems, or even the absence of phase II 330 metabolism in vitro. These factors were not explored in this work but provide interesting avenues for future 331 investigation. 332 3.6 Translation to routine screening 333 The ability of locally implemented protocols to detect furazadrol administration was assessed by subjecting 334 the in vivo urine samples to routine screening (section 2.7). Duplicates of each of the in vivo samples were 335 manually adjusted to pH 5.0-5.5 and subjected to enzyme hydrolysis using H. pomatia β-glucuronidase. 336
Subsequent purification by solid-phase extraction afforded the urinary steroid metabolites in a combined 337 neutral and acidic fraction. Positive mode LC-MS analysis of this fraction detected F (major), IF and EF and 338 these were matched against reference materials. Additionally, an oxidised and hydroxylated furazadrol 339 metabolite (M9) was detected. Both F and IF provide suitable targets for confirmatory analysis, with LOD 340 estimated at 0.2 ng mL -1 . The short detection period for furazadrol shown by this work (section 3.4) 341 illustrates the benefits of out-of-competition testing strategies to complement race day sample collection 342 for effective surveillance of anabolic steroid misuse. 343
Conclusions
344
Designer steroids such as furazadrol pose a significant threat to the integrity of sport if left unchecked. The 345 metabolism of furazadrol was studied by in vivo and in vitro methods for the first time. Furazadrol 17-346 sulfate (FS) and furazadrol 17-glucuronide (FG) metabolites were detected in vivo up to one day followinghydroxylation, and oxidation and hydroxylation, together with sulfate or glucuronide conjugation were also 349 observed (Figure 4) . These phase II metabolites were subjected to enzymatic hydrolysis by E. coli β-350 glucuronidase and P. aeruginosa arylsulfatase to provide further evidence of phase I metabolite identity. 351
The hydrolysed in vivo metabolites were compared to those obtained from an in vitro study, with 352 reasonable qualitative agreement between systems. These investigations allowed the identification of the 353 key metabolites that can be incorporated into anti-doping screening and confirmation protocols. 354 
